Cargando…

Management of uterine sarcomas and prognostic indicators: real world data from a single-institution

BACKGROUND: Uterine sarcomas consist a heterogeneous group of mesenchymal gynecological malignancies with unclear therapeutic recommendations and unspecific but poor prognosis, since they usually metastasize and tend to recur very often, even in early stages. METHODS: We retrospectively analyzed all...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyriazoglou, Anastasios, Liontos, Michael, C Ziogas, Dimitrios, Zagouri, Flora, Koutsoukos, Kostantinos, Tsironis, Giorgos, Tsiara, Anna, Kaparelou, Maria, Zakopoulou, Roubini, Thomakos, Nikolaos, Haidopoulos, Dimitrios, Papaspyrou, Irene, Rodolakis, Alexandros, Bamias, Aristotelis, Dimopoulos, Meletios Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292121/
https://www.ncbi.nlm.nih.gov/pubmed/30541504
http://dx.doi.org/10.1186/s12885-018-5156-1
_version_ 1783380353801519104
author Kyriazoglou, Anastasios
Liontos, Michael
C Ziogas, Dimitrios
Zagouri, Flora
Koutsoukos, Kostantinos
Tsironis, Giorgos
Tsiara, Anna
Kaparelou, Maria
Zakopoulou, Roubini
Thomakos, Nikolaos
Haidopoulos, Dimitrios
Papaspyrou, Irene
Rodolakis, Alexandros
Bamias, Aristotelis
Dimopoulos, Meletios Athanasios
author_facet Kyriazoglou, Anastasios
Liontos, Michael
C Ziogas, Dimitrios
Zagouri, Flora
Koutsoukos, Kostantinos
Tsironis, Giorgos
Tsiara, Anna
Kaparelou, Maria
Zakopoulou, Roubini
Thomakos, Nikolaos
Haidopoulos, Dimitrios
Papaspyrou, Irene
Rodolakis, Alexandros
Bamias, Aristotelis
Dimopoulos, Meletios Athanasios
author_sort Kyriazoglou, Anastasios
collection PubMed
description BACKGROUND: Uterine sarcomas consist a heterogeneous group of mesenchymal gynecological malignancies with unclear therapeutic recommendations and unspecific but poor prognosis, since they usually metastasize and tend to recur very often, even in early stages. METHODS: We retrospectively analyzed all female patients with uterine sarcomas treated in our institution over the last 17 years. Clinico-pathological data, treatments and outcomes were recorded. Kaplan-Meier curves were plotted and time-to-event analyses were estimated using Cox regression. RESULTS: Data were retrieved from 61 women with a median age of 53 (range: 27–78) years, at diagnosis. Fifty-one patients were diagnosed with leiomyosarcoma (LMS), 3 with high grade endometrial stromal sarcoma (ESS), 5 with undifferentiated uterine sarcoma (UUS), 1 with Ewing sarcoma (ES) and 1 with Rhabdomyosarcoma (RS). 24 cases had stage I, 7 stage II, 14 stage III and 16 stage IV disease. Median disease-free survival (DFS) in adjuvant approach was 18.83 months, and median overall survival (OS) 31.07 months. High mitotic count (> 15 mitoses) was significantly associated with worse OS (P < 0.001) and worse DFS (P = 0.028). CONCLUSIONS: Mitotic count appears to be independent prognostic factor while further insights are needed to improve adjuvant and palliative treatment of uterine sarcomas.
format Online
Article
Text
id pubmed-6292121
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62921212018-12-17 Management of uterine sarcomas and prognostic indicators: real world data from a single-institution Kyriazoglou, Anastasios Liontos, Michael C Ziogas, Dimitrios Zagouri, Flora Koutsoukos, Kostantinos Tsironis, Giorgos Tsiara, Anna Kaparelou, Maria Zakopoulou, Roubini Thomakos, Nikolaos Haidopoulos, Dimitrios Papaspyrou, Irene Rodolakis, Alexandros Bamias, Aristotelis Dimopoulos, Meletios Athanasios BMC Cancer Research Article BACKGROUND: Uterine sarcomas consist a heterogeneous group of mesenchymal gynecological malignancies with unclear therapeutic recommendations and unspecific but poor prognosis, since they usually metastasize and tend to recur very often, even in early stages. METHODS: We retrospectively analyzed all female patients with uterine sarcomas treated in our institution over the last 17 years. Clinico-pathological data, treatments and outcomes were recorded. Kaplan-Meier curves were plotted and time-to-event analyses were estimated using Cox regression. RESULTS: Data were retrieved from 61 women with a median age of 53 (range: 27–78) years, at diagnosis. Fifty-one patients were diagnosed with leiomyosarcoma (LMS), 3 with high grade endometrial stromal sarcoma (ESS), 5 with undifferentiated uterine sarcoma (UUS), 1 with Ewing sarcoma (ES) and 1 with Rhabdomyosarcoma (RS). 24 cases had stage I, 7 stage II, 14 stage III and 16 stage IV disease. Median disease-free survival (DFS) in adjuvant approach was 18.83 months, and median overall survival (OS) 31.07 months. High mitotic count (> 15 mitoses) was significantly associated with worse OS (P < 0.001) and worse DFS (P = 0.028). CONCLUSIONS: Mitotic count appears to be independent prognostic factor while further insights are needed to improve adjuvant and palliative treatment of uterine sarcomas. BioMed Central 2018-12-13 /pmc/articles/PMC6292121/ /pubmed/30541504 http://dx.doi.org/10.1186/s12885-018-5156-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kyriazoglou, Anastasios
Liontos, Michael
C Ziogas, Dimitrios
Zagouri, Flora
Koutsoukos, Kostantinos
Tsironis, Giorgos
Tsiara, Anna
Kaparelou, Maria
Zakopoulou, Roubini
Thomakos, Nikolaos
Haidopoulos, Dimitrios
Papaspyrou, Irene
Rodolakis, Alexandros
Bamias, Aristotelis
Dimopoulos, Meletios Athanasios
Management of uterine sarcomas and prognostic indicators: real world data from a single-institution
title Management of uterine sarcomas and prognostic indicators: real world data from a single-institution
title_full Management of uterine sarcomas and prognostic indicators: real world data from a single-institution
title_fullStr Management of uterine sarcomas and prognostic indicators: real world data from a single-institution
title_full_unstemmed Management of uterine sarcomas and prognostic indicators: real world data from a single-institution
title_short Management of uterine sarcomas and prognostic indicators: real world data from a single-institution
title_sort management of uterine sarcomas and prognostic indicators: real world data from a single-institution
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292121/
https://www.ncbi.nlm.nih.gov/pubmed/30541504
http://dx.doi.org/10.1186/s12885-018-5156-1
work_keys_str_mv AT kyriazoglouanastasios managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT liontosmichael managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT cziogasdimitrios managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT zagouriflora managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT koutsoukoskostantinos managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT tsironisgiorgos managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT tsiaraanna managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT kapareloumaria managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT zakopoulouroubini managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT thomakosnikolaos managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT haidopoulosdimitrios managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT papaspyrouirene managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT rodolakisalexandros managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT bamiasaristotelis managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution
AT dimopoulosmeletiosathanasios managementofuterinesarcomasandprognosticindicatorsrealworlddatafromasingleinstitution